United Kingdom National Guideline on the Management of the viral hepatitides A,B and C 2015

Abstract

Get full access to this article

View all access options for this article.

References

Health Protection Agency. Hepatitis A. Laboratory reports, England and Wales 1992–2010, http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1195733853946 (accessed 5 August 2014).

Roberts

Palmer

. Exposure to school children as a risk factor in a community outbreak of hepatitis A in young adults: a case control study. Epidemiol Infect 2006; 134: 803–807.

Shapiro

Margolis

. Worldwide epidemiology of hepatitis A virus infection. J Hepatol 1993; 18(Suppl 2): S11–S14.

Botelho-Nevers

Gautret

. Outbreaks associated to large open air festivals, including music festivals, 1980 to 2012. Euro Surveill 2013; 18: 1025–1025.

Martin

Lemon

. Hepatitis A virus: from discovery to vaccines. Hepatology 2006; 43(Suppl 1): S164–S172.

Schmid

Fretz

Buchner

. Foodborne outbreak of hepatitis A, November 2007–January 2008. Austria Eur J Clin Microbiol Infect Dis 2009; 28: 385–391.

Rowe

Tanner

Gregory

. Hepatitis A outbreak epidemiologically linked to a food handler in Melbourne, Victoria. Commun Dis Intell Q Rep 2009; 33: 46–48.

Van Rijckevorsel

Sonder

Bovee

. Trends in hepatitis A, B, and shigellosis compared with gonorrhea and syphilis in men who have sex with men in Amsterdam, 1992–2006. Sex Trans Dis 2008; 35: 930–934.

Stene-Johansen

Tjon

Schreier

. Molecular epidemiological studies show that hepatitis A virus is endemic among active homosexual men in Europe. J Med Virol 2007; 79: 356–365.

10.

Cotter

Sansom

Long

. Outbreak of hepatitis A among men who have sex with men: implications for hepatitis A vaccination strategies. J Infect Dis 2003; 187: 1235–1240.

11.

Bell

Ncube

Hansell

. An outbreak of hepatitis A among young men associated with having sex in public venues. Commun Dis Public Health 2001; 4: 163–170.

12.

Urbanus

van Houdt

van de Laar

. Viral hepatitis among men who have sex with men, epidemiology and public health consequences. Euro Surveil 2009; 14: 1025–1025.

13.

Reintjes

Bosman

de Zwart

. Outbreak of hepatitis A in Rotterdam associated with visits to ‘darkrooms’ in gay bars. Commun Dis Public Health 1999; 2: 43–46.

14.

Dodge

Reece

Herbenick

. Relations between sexually transmitted infection diagnosis and sexual compulsivity in a community-based sample of men who have sex with men. Sex Trans Infect 2008; 84: 324–327.

15.

Ross

JDC

Ghanem

Tariq

. Seroprevalence of hepatitis A immunity in male genitourinary medicine clinic attenders: a case control study of heterosexual and homosexual men. Sex Transm Infect 2002; 78: 174–179.

16.

Corona

Stroffolini

Giglio

. Lack of evidence for increased risk of hepatitis A infection in homosexual men. Epidemiol Infect 1999; 123: 89–93.

17.

Jin

Prestage

Zablotska

. High rates of sexually transmitted infections in HIV positive homosexual men: data from two community based cohorts. Sex Transm Infect 2007; 83: 397–399.

18.

Gallego

Robles

Palacios

. Impact of acute hepatitis A virus (HAV) infection on HIV viral load in HIV-infected patients and influence of HIV infection on acute HAV infection. J Int Assoc Phys AIDS Care (Chic) 2011; 10: 40–42.

19.

Ngui

Granerod

Jewes

. Outbreaks of hepatitis A in England and Wales associated with two co-circulating hepatitis A virus strains. J Med Virol 2008; 80: 1181–1188.

20.

Woodruff

Vazquez

. Prevalence of hepatitis virus infections in an institution for persons with developmental disabilities. Am J Ment Retard 2002; 107: 278–292.

21.

Chudy

Budek

Keller-Stanislawski

. A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool. J Med Virol 1999; 57: 91–99.

22.

Soucie

Robertson

Bell

. Hepatitis A virus infections associated with clotting factor concentrate in the United States. Transfusion 1998; 38: 573–579.

23.

Polish

Robertson

Khanna

. Excretion of hepatitis A virus (HAV) in adults: comparison of immunologic and molecular detection methods and relationship between HAV positivity and infectivity in tamarins. J Clin Microbiol 1999; 37: 3615–3617.

24.

Zuckerman

Viral hepatitis. In: Cook

Zumla

(eds). Manson’s tropical diseases, London: Saunders, 2009, pp. 697–714.

25.

Jeong

Lee

. Hepatitis A: clinical manifestations and management. Intervirology 2010; 53: 15–19.

26.

Mackinney-Novelo

Barahona-Garrido

Castillo-Albarran

. Clinical course and management of acute hepatitis A infection in adults. Ann Hepatol 2012; 11: 652–657.

27.

Lee

Squires

Jr Nyberg

. Acute liver failure: summary of a workshop. Hepatology 2008; 47: 1401–1415.

28.

Pramoolsinsap

. Acute hepatitis A and immunity to hepatitis A virus in hepatitis B virus carriers and in HBV- or hepatitis C virus-related chronic liver diseases in Thailand. J Viral Hepat 2000; 7: 11–12.

29.

Inoue

Yoshiba

Yotsuyanagi

. Chronic hepatitis A with persistent viral replication. J Med Virol 1996; 50: 322–324.

30.

Sookoian

. Liver disease during pregnancy: acute viral hepatitis. Ann Hepatol 2006; 5: 231–236.

31.

Elina

Ben-Dov

Shapira

. Acute hepatitis A infection in pregnancy is associated with high rates of gestational complications and preterm labor. Gastroenterology 2006; 130: 1129–1134.

32.

Renge-Ramesh

Dani

Chitambar

. Vertical transmission of hepatitis A. Indian J Pediatr 2002; 69: 535–536.

33.

Erkan

Kutlu

Cullu

. A case of vertical transmission of hepatitis A infection. Acta Paediatrica 1998; 87: 1008–1009.

34.

Charuworn

Cheung

. Diagnostic markers for hepatitis virus infection. Expert Opin Med Diagn 2008; 2: 303–314.

35.

Lee

Kim

Lee

. Window period of anti-hepatitis A virus immunoglobulin M antibodies in diagnosing acute hepatitis A. Eur J Gastroenterol Hepatol 2013; 2: 665–668.

36.

Public Health England. Hepatitis E: symptoms, transmission, treatment and prevention, www.gov.uk/government/publications/hepatitis-e-symptoms-transmission-prevention-treatment/hepatitis-e-symptoms-transmission-treatment-and-prevention (accessed 7 December 2014).

37.

Oxman

Scott

Sellors

. Partner notification for sexually transmitted diseases: an overview of the evidence. Canadian J Public Health 1994; 85(Suppl 1): S41–S47.

38.

BASHH. Guidance on reporting cases of hepatitis in GU medicine clinics, www.bashh.org/documents/4736.pdf (accessed 5 August 2014).

39.

Michielsen

Van Damme

. Viral hepatitis and pregnancy. Acta Gastroenterologica Belgica 1999; 62: 21–29.

40.

McClean H, Radcliffe K, Sullivan A, et al. 2012 BASHH statement on partner notification for sexually transmissible infections, www.bashh.org/documents/2012%20Partner%20Notification%20Statement.pdf (accessed 7 December 2014).

41.

Public Health England. Hepatitis A: the green book, chapter 17, www.gov.uk/government/uploads/system/uploads/attachment_data/file/147954/Green-Book-Chapter-17.pdf (2013, accessed 5 August 2014).

42.

Health Protection Agency. Guidance for the prevention and control of hepatitis A infection, www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1259152095231 (accessed 5 August 2014).

43.

Van Damme

Van

. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis 2007; 5: 79–84.

44.

Rendi-Wagner Korinek

Winkler

. Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population. Vaccine 2007; 25: 927–931.

45.

Kourkounti

Papaizos

Leuow

. Hepatitis A vaccination and immunological parameters in HIV-infected patients. Viral Immunol 2013; 26: 357–363.

46.

Mena

Garcia-Basteiro

Llupia

. Factors associated with the immune response to hepatitis A vaccination in HIV-infected patients in the era of highly active antiretroviral therapy. Vaccine 2013; 31: 3668–3674.

47.

Wilkins

Nelson

Agarwal

. BHIVA guidelines: Management of hepatitis viruses in adults infected with HIV 2013. HIV Med 2013; 14(Suppl. 4): 1–71.

48.

Diaz

Law

Subramanya

. Long-term antibody persistence induced by a combined hepatitis A and B vaccine in children and adolescents. Vaccine 2008; 26: 1759–1763.

49.

Van

Leroux

Van-Damme

. Ten-year antibody persistence induced by hepatitis A and B vaccine (Twinrix) in adults. Travel Med Infect Dis 2007; 5: 171–175.

50.

Corona

Stroffolini

Giglio

. Lack of evidence for increased risk of hepatitis A infection in homosexual men. Epidemiol Infect 1999; 123: 89–93.

51.

O-Riordan

Goh

Lamba

. Increasing hepatitis A IgG prevalence rate in men who have sex with men attending a sexual health clinic in London: implications for immunization policy. Int J STD AIDS 2007; 18: 707–710.

52.

HPA. Acute hepatitis B (England): annual report for 2011. Infection reports, Volume 6, Number 34, www.hpa.org.uk/hpr/archives/2012/hpr3412.pdf (accessed 5 August 2014).

53.

Gerlich

. Medical Virology of Hepatitis B: how it began and where we are now. Virol J 2013; 10: 239–239.

54.

Gilson

de Ruiter

Waite

. Hepatitis B virus infection in patients attending a genitourinary medicine clinic: risk factors and vaccination coverage. Sex Trans Infect 1998; 74: 110–115.

55.

Struve

Giesecke

Lindh

. Heterosexual contact as a major route for transmission of acute hepatitis B amongst adults. J Infect 1990; 20: 111–121.

56.

Huo

Huang

. Evidence of transmission of hepatitis B to spouses from sequence analysis of the viral genome. J Gastroenterol Hepatol 1998; 13: 1138–1142.

57.

Hyams

Phillips

Tejada

. Hepatitis B in a highly active prostitute population: evidence for a low risk of antigenaemia. J Infect Dis 1990; 162: 295–298.

58.

Ward

Day

Weber

. Risky business: health and safety in the sex industry over a 9 year period. Sex Trans Infect 1999; 75: 340–343.

59.

Public Health England. Hepatitis B: the green book (chapter 18) www.gov.uk/government/uploads/system/uploads/attachment_data/file/263311/Green_Book_Chapter_18_v2_0.pdf (2013, accessed 5 August 2014).

60.

Walsh

Maguire

Carrington

. Outbreak of hepatitis B in a acupuncture clinic. Commun Dis Public Health 1999; 2: 137–140.

61.

Palmovic

Crnjakovic-Palmovic

. Prevention of hepatitis B virus (HBV) infection in health-care workers after accidental exposure: a comparison of two prophylactic schedules. Infection 1993; 21: 42–45.

62.

Vogt

Perz

Van-Houten

Jr . An outbreak of hepatitis B virus infection among methamphetamine injectors: the role of sharing injection drug equipment. Addiction 2006; 101: 726–730.

63.

Cramp

Grundy

Perinpanayagam

. Seroprevalence of hepatitis B and C virus in two institutions caring for mentally handicapped adults. J Roy Soc Med 1996; 89: 401–402.

64.

Wallace

. Clinical audit of gastrointestinal conditions occurring among adults with Down syndrome attending a specialist clinic. J Intellect Dev Disabil 2007; 32: 45–50.

65.

Hyams

. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995; 20: 992–1000.

66.

Hann

Han

Block

. Symptomatology and health attitudes of chronic hepatitis B patients in the USA. J Viral Hepat 2008; 15: 42–51.

67.

Keeffe

Dieterich

Han

SHB

. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 936–962.

68.

Papatheodoridis

Manolakopoulos

Dusheiko

. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008; 8: 167–178.

69.

Hoofnagle

. Chronic hepatitis B. N Engl J Med 1990; 323: 337–339.

70.

Thomas

. Best practice in the treatment of chronic hepatitis B: a summary of the European Viral Hepatitis Educational Initiative (EVHEI). J Hepatol 2007; 47: 588–597.

71.

Benhamou

. Hepatitis B in the HIV-coinfected patient. J Acquir Immune Defic Syndr 2007; 45(Suppl 2): S57–S65.

72.

Katz

Fraser

Gafter

. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat 2008; 15: 89–102.

73.

Giovanna

Bortolotti

Francesco

. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335–352.

74.

Lin

Verslype

van-Pelt

. Viral interaction and clinical implications of coinfection of hepatitis C virus with other hepatitis viruses. Eur J Gastroenterol Hepatol 2006; 18: 1311–1319.

75.

Chiaramonte

Stroffolini

VianA . Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999; 85: 2132–2137.

76.

Thio

Seaberg

Skolasky

Jr . HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921–1926.

77.

Sagnelli

Coppola

Pisaturo

. Clinical and virological improvement of hepatitis B virus-related or hepatitis C virus-related chronic hepatitis with concomitant hepatitis A virus infection. Clin Infect Dis 2006; 42: 1536–1543.

78.

National Institute for Health and Care Excellence. Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young people and adults, www.nice.org.uk/Guidance/CG165 (accessed 5 August 2014).

79.

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227–242.

80.

Sun

Yan

. Lamivudine treatment is associated with improved survival in fulminant hepatitis B. Liver Int 2011; 31: 499–506.

81.

De Socio

Sgrelli

Tosti

. Severe acute hepatitis B treated with entecavir. Med J Hematol Infect Dis 2011; 3: e2011010–e2011010.

82.

Hosaka

Suzuki

Kobayashi

. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58: 98–107.

83.

Kim

Berg

Loomba

. Long term tenofovirdisoproxilfumarate (TDF) therapy and the risk of hepatocellular carcinoma. J Hepatol 2013; 58: S19–S19.

84.

Lai

Gane

LiawYF . Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576–2588.

85.

Chan

HLY

Heathcote

Marcellin

. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007; 147: 745–754.

86.

Tan

Degertekin

Wong

. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008; 48: 391–398.

87.

Soriano

de Mendoza

Fernández-Montero

. Management and treatment of chronic hepatitis B in HIV-positive patients. Ann Med 2014; 46: 290–296.

88.

Benhamou

. Treatment algorithm for chronic hepatitis B in HIV-infected patients. J Hepatol 2006; 44(Suppl): S90–S94.

89.

Schmutz

Nelson

Lutz

. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 2006; 20: 1951–1954.

90.

Peters

Andersen

Lynch

. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006; 44: 1110–1116.

91.

Sherman

. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005; 25: 143–154.

92.

Gambarin

. Hepatitis B in pregnancy. Clin Liver Dis 2007; 11: 945–963.

93.

ter-Borg

Leemans

de-Man

. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat 2008; 15: 37–41.

94.

Zuckerman

. Review: hepatitis B immune globulin for prevention of hepatitis B infection. J Med Virol 2007; 79: 919–921.

95.

HPA. Immunoglobulin Handbook: hepatitis B, www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947401259 (accessed 5 August 2014).

96.

Mast

Weinbaum

Fiore

. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55: 1–33.

97.

Connor

Blatter

Beran

. Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated administration schedule. J Travel Med 2007; 14: 9–15.

98.

Ahmed

Volpellier

Forster

. The use of the super accelerated hepatitis B vaccination regimen in a north London sexual assault referral centre (SARC). J Forensic Leg Med 2007; 14: 72–74.

99.

Keystone

Hershey

. The underestimated risk of hepatitis A and hepatitis B: benefits of an accelerated vaccination schedule. Int J Infect Dis 2008; 12: 3–11.

100.

Kallinowski

Jilg

Buchholz

. Immunogenicity of an accelerated vaccination regime with a combined hepatitis a/b vaccine in patients with chronic hepatitis C. Z Gastroenterol 2003; 41: 983–990.

101.

Baral

Sherman

Millson

. Vaccine immunogenicity in injecting drug users: a systematic review. Lancet Infect Dis 2007; 7: 667–674.

102.

Poorolajal

Mahmoodi

Majdzadeh

. Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis. Vaccine 2010; 28: 623–631.

103.

Overton

Sungkanuparph

Powderly

. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005; 41: 1045–1048.

104.

Paitoonpong

Suankratay

. Immunological response to hepatitis B vaccination in patients with AIDS and virological response to highly active antiretroviral therapy. Scand J Infect Dis 2008; 40: 54–58.

105.

de-Vries-Sluijs

TEMS

Hansen

van-Doornum

GJJ

. A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. J Infect Dis 2008; 197: 292–294.

106.

Fonseca

Pang

de Paula Cavalheiro

. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005; 23: 2902–2908.

107.

BASHH Clinical Effectiveness Group. 2014 BASHH CEG guidance on tests for sexually transmitted infections, www.bashh.org/documents/STI%20testing%20tables%202014.docx (accessed 2 April 2015).

108.

Thio

. Diagnosis, diagnostic tests and monitoring of hepatitis B virus in monoinfected and HIV-coinfected patients. Antivir Ther 2007; 12(Suppl 3): H25–H31.

109.

Clemens

Sanger

Kruppenbacher

. Booster immunisation of low- and non-responders after a standard three dose hepatitis B vaccine schedule – results of post-marketing surveillance. Vaccine 1997; 15: 349–352.

110.

Puro

De-Carl

Cicalini

. European recommendations for the management of healthcare workers occupationally exposed to hepatitis B virus and hepatitis C virus. Euro Surveill 2005; 10: 260–264.

111.

Goldwater

. Randomized, comparative trial of 20 micrograms vs 40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders. Vaccine 1997; 15: 353–356.

112.

Pichichero

. Improving vaccine delivery using novel adjuvant systems. Hum Vaccin 2008; 4: 262–270.

113.

Kundi

. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 2007; 6: 133–140.

114.

Hoebe

Vermeiren

Dukers-Muijrers

. Revaccination with Fendrix® or HBVaxPro® results in better response rates than does revaccination with three doses of Engerix-B® in previous non-responders. Vaccine 2012; 30: 6734–6737.

115.

de Silva

Green

Cole

. Successful use of Fendrix in HIV-infected non-responders to standard hepatitis B vaccines. J Infect 2014; 68: 397–399.

116.

Van-Damme

Van

. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis 2007; 5: 79–84.

117.

Jack

Hall

Maine

. What level of hepatitis B antibody is protective? J Infect Dis 1999; 179: 489–492.

118.

McMahon

Bruden

Petersen

. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005; 142: 333–341.

119.

Chiang

. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 2008; 197: 1419–1426.

120.

Wistrom

Ahlm

Lundberg

. Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose. Vaccine 1999; 17: 2162–2165.

121.

van-der-Sande

MAB

Mendy

Waight

. Similar long-term vaccine efficacy of two versus three doses of HBV vaccine in early life. Vaccine 2007; 25: 1509–1512.

122.

Cross

TJS

Rizzi

Horner

. The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol 2008; 80: 277–282.

123.

Heller

Rotman

Koh

. Hepatitis d. Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther 2014; 40: 93–104.

124.

Guedj

Rotman

Cotler

. Understanding early serum hepatitis D virus and HBsAg kinetics during pegylated interferon-alfa therapy via mathematical modeling. Hepatology 2014; 60: 1902–1910.

125.

Mohd Hanafiah

Groeger

Flaxman

. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333–1342.

126.

Public Health England. Hepatitis C in the UK. 2014 report, www.gov.uk/government/uploads/system/uploads/attachment_data/file/337115/HCV_in_the_UK_2014_24_July.pdf (accessed 5 August 2014).

127.

Ansaldi

Orsi

Sticchi

. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol 2014; 20: 9633–9652.

128.

Lee

Yang

Yuan

. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol 2014; 20: 9270–9280.

129.

Messina

Humphreys

Flaxman

. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61: 77–87.

130.

Roy

Boivin

. Risk of hepatitis C virus transmission through drug preparation equipment: a systematic and methodological review. J Viral Hepat 2008; 15: 279–292.

131.

Persico

Perrotta

Persico

. Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years. J Viral Hepat 2006; 13: 290–296.

132.

Massard

Ratziu

Thabut

. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006; 44(Suppl): S19–S24.

133.

Esteban

Sauleda

Quer

. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008; 48: 148–162.

134.

Elder

Paterson

. Sharps injuries in UK health care: a review of injury rates, viral transmission and potential efficacy of safety devices. Occup Med (Lond) 2006; 56: 566–574.

135.

Sawayama

Hayashi

Kakuda

. Hepatitis C virus infection in institutionalized psychiatric patients: possible role of transmission by razor sharing. Digest Dis Sci 2000; 45: 351–356.

136.

Vandelli

Renzo

Romanò

. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am J Gastroenterol 2004; 99: 855–859.

137.

McMahon

Pouget

Tortu

. Individual and couple-level risk factors for hepatitis C infection among heterosexual drug users: a multilevel dyadic analysis. J Infect Dis 2007; 195: 1572–1581.

138.

Jebbari

Alexander

Ward

. Update on lymphogranuloma venereum in the United Kingdom. Sex Transm Infect 2007; 83: 324–326.

139.

Marcellin

Lorente

Demoulin

. Comparison of risk factors in HIV-infected men who have sex with men, coinfected or not with hepatitis C virus (ANRS VESPA2 French cross-sectional national survey). Sex Transm Infect 2015; 91: 21–23.

140.

Vanhommerig

Stolte

Lambers

. Stabilizing incidence of hepatitis C virus infection among men who have sex with men in Amsterdam. J AIDS 2014; 66: e111–e115.

141.

Kao

Liu

Chen

. Low incidence of hepatitis C virus transmission between spouses: a prospective study. J Gastroenterol Hepatol 2000; 15: 391–395.

142.

Marincovich

Castilla

del-Romero

. Absence of hepatitis C virus transmission in a prospective cohort of heterosexual serodiscordant couples. Sex Transm Infect 2003; 79: 160–162.

143.

Taylor

Hutchinson

Gilchrist

. Prevalence and determinants of hepatitis C virus infection among female drug injecting sex workers in Glasgow. Harm Reduct J 2008; 5: 11–11.

144.

Hope

McVeigh

Marongiu

. Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study. BMJ Open 2013; 3: e003207–e003207.

145.

Vescio

Longo

Babudieri

. Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. J Epidemiol Community Health 2008; 62: 305–313.

146.

Macías

Palacios

Claro

. High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack. Liver Int 2008; 28: 781–786.

147.

Zhang

. Drug abuse, innate immunity and hepatitis C virus. Rev Med Virol 2006; 16: 311–327.

148.

Benova

Mohamoud

Calvert

. Vertical transmission of hepatitis C Virus: systematic review and meta-analysis. Clin Infect Dis 2014; 59: 765–773.

149.

Cottrell

Chou

Wasson

. Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2013; 158: 109–113.

150.

England

Thorne

Harris

. The impact of mode of acquisition on biological markers of paediatric hepatitis C virus infection. J Viral Hepat 2011; 18: 533–541.

151.

Mok

Pembrey

Tovo

. When does mother to child transmission of hepatitis C virus occur? Arch Dis Child 2005; 90: F156–F160.

152.

Azzari

Moriond-M Indolfi

. Higher risk of hepatitis C virus perinatal transmission from drug user mothers is mediated by peripheral blood mononuclear cell infection. J Med Virol 2008; 80: 65–71.

153.

Neal

Jones

Killey

. Risk factors for hepatitis C virus infection. A case-control study of blood donors in the Trent Region (UK). Epidemiol Infect 1994; 112: 595–601.

154.

Vidimliski

Nikolov

Geshkovska

. Review: occult hepatitis C virus infection: still remains a controversy. J Med Virol 2014; 86: 1491–1498.

155.

Thomson

Nastouli

Main

. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS 2009; 23: 89–93.

156.

Nastouli

Thomson

Karayiannis

. Diagnosing acute hepatitis C in HIV-infected patients: Nucleic acid testing compared with antibody and antigen–antibody detecting methods. J Clin Virol 2009; 44: 78–80.

157.

Lefilliatre

Villeneuve

. Fulminant hepatitis A in patients with chronic liver disease. Can J Public Health 2000; 91: 168–170.

158.

Deterding

Tegtmeyer

Cornberg

. Hepatitis A virus infection suppresses hepatitis C virus replication and may lead to clearance of HCV. J Hepatol 2006; 45: 770–778.

159.

Harris

Eldridge

Harbour

. Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type? J Viral Hepat 2007; 14: 213–220.

160.

Kallman

O-Neil

Larive

. Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci 2007; 52: 2531–2539.

161.

Nattermann

Timm

Nischalke

. The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5Δ32 mutation. J Hepatol 2011; 55: 1201–1206.

162.

Singal

Anand

. Mechanisms of synergy between alcohol and hepatitis C virus. J Clin Gastroenterol 2007; 41: 761–772.

163.

Bruno

Crosignani

Maisonneuve

. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007; 46: 1350–1356.

164.

Hui

Zhang

Shek

. Disease progression in Chinese chronic hepatitis C patients with persistently normal alanine aminotransaminase levels. Aliment Pharmacol Ther 2007; 25: 1283–1292.

165.

Roshan

Guzman

. Histological and clinical characteristics of patients with chronic hepatitis C and persistently normal alanine aminotransferase levels. Hepat Res Treat 2014; 2014: 760943–760943.

166.

Harris

Ramsay

Andrews

. Survival of a national cohort of hepatitis C virus infected patients, 16 years after exposure. Epidemiol Infect 2006; 134: 472–477.

167.

Levine

Sanderson

Ploutz

. Assessment of fibrosis progression in untreated Irish women with chronic hepatitis C contracted from immunoglobulin anti-D. Clin Gastroenterol Hepatol 2006; 4: 1271–1277.

168.

Sangiovanni

Prati

Fasani

. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303–1310.

169.

Lo Re

3rd Kallan

Tate

. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med 2014; 160: 369–379.

170.

Gupta

. Hepatitis C virus and HIV type 1 co-infection. Infect Dis Rep 2013; 5(Suppl 1): e7–e7.

171.

Pineda

García

Aguilar

. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007; 46: 622–630.

172.

van der Helm

Geskus

Sabin

. Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. Gastroenterology 2013; 144: 751–760.

173.

Sagnelli

Santantonio

Coppola

. Acute hepatitis C: clinical and laboratory diagnosis, course of the disease, treatment. Infection 2014; 42: 601–610.

174.

Contreras

Tinoco

Celis

. Hepatitis C antibody intraassay correlation: is retest in duplicate necessary? Transfusion 2007; 47: 1686–1690.

175.

Hadlich

Alvares-Da-Silva

Dal-Molin

. Hepatitis C virus (HCV) viremia in HIV-infected patients without HCV antibodies detectable by third-generation enzyme immunoassay. J Gastroenterol Hepatol 2007; 22: 1506–1509.

176.

Gower

Estes

Hindman

. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61(Suppl 1): S45–S57.

177.

EASL. Recommendation on treatment of hepatitis C 2014, http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-C/index.html#p=I (accessed 5 August 2014).

178.

. Liver fibrosis evaluation by ARFI and APRI in chronic hepatitis C. World J Gastroenterol 2014; 20: 9528–9533.

179.

Tsochatzis

Crossan

Longworth

. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. Hepatology 2014; 60: 832–843.

180.

Del Poggio

Olmi

Ciccarese

. Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2014; 12: 1927–1933.

181.

CalleriG Cariti

Gaiottino

. A short course of pegylated interferon-alpha in acute HCV hepatitis. J Viral Hepat 2007; 14: 116–121.

182.

Santantonio

Fasano

Sagnelli

. Acute hepatitis C: a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin. Hepatology 2014; 59: 2101–2109.

183.

Beinhardt

Payer

Datz

. A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection. J Hepatol 2013; 59: 972–977.

184.

European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS 2011; 25: 399–409.

185.

Nookathota

Mukherjee

. Antiviral therapy for chronic hepatitis C in 2014. Expert Rev Clin Pharmacol 2014; 7: 499–505.

186.

AASLD. Recommendations for testing, managing, and treating hepatitis C, www.hcvguidelines.org/full-report-view (accessed 5 August 2014).

187.

Squadrito

Cacciola

Alibrandi

. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. J Hepatol 2013; 59: 696–700.

188.

Ingiliz

Krznaric

Stellbrink

. Multiple hepatitis C virus (HCV) reinfections in HIV-positive men who have sex with men: no influence of HCV genotype switch or interleukin-28B genotype on spontaneous clearance. HIV Med 2014; 15: 355–361.

189.

Sacks-Davis

Aitken

Higgs

. High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study. PLoS One 2013; 8: e80216–e80216.

190.

Ward

Lee

. Experience of acute hepatitis C and HIV co-infection in an inner city clinic in the UK. J Int AIDS Soc 2014; 17(Suppl 3): 19639–19639.

191.

Urbanus

Van De Laar

Geskus

. Trends in hepatitis C virus infections among MSM attending a sexually transmitted infection clinic; 1995–2010. AIDS 2014; 28: 781–790.

192.

British HIV Association. Standards of care for people living with HIV, www.bhiva.org/documents/Standards-of-care/BHIVAStandardsA4.pdf (2013, accessed 5 August 2014).

193.

Prati

. Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. J Hepatol 2006; 45: 607–616.

194.

Van-Den-Berg

Smit

Van-Brussel

. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007; 102: 1454–1462.

195.

Mateu

Treloar

Calatayud

. How can hepatitis C be prevented in the long term? Int J Drug Policy 2007; 18: 338–340.

196.

Wright

NMJ

Tompkins

CNE

. A review of the evidence for the effectiveness of primary prevention interventions for hepatitis C among injecting drug users. Harm Reduct J 2006; 3: 27–27.